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ABSTRACT
The endothelium plays an important role in cancer metastasis,
but the mechanisms involved are still not clear. In the present
work, we characterised the changes in endothelial function
at early and late stages of breast cancer progression in an
orthotopic model of murine mammary carcinoma (4T1 cells).
Endothelial function was analysed based on simultaneous
microflow liquid chromatography–tandem mass spectrometry using
multiple reaction monitoring (microLC/MS-MRM) quantification of
12 endothelium-related biomarkers, including those reflecting
glycocalyx disruption – syndecan-1 (SDC-1), endocan (ESM-1);
endothelial inflammation – vascular cell adhesion molecule 1
(VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E-selectin
(E-sel); endothelial permeability – fms-like tyrosine kinase 1 (FLT-1),
angiopoietin 2 (Angpt-2); and haemostasis – von Willebrand factor
(vWF), tissue plasminogen activator (t-PA), plasminogen activator
inhibitor 1 (PAI-1), as well as those that are pathophysiologically
linked to endothelial function – adrenomedullin (ADM) and
adiponectin (ADN). The early phase of metastasis in mouse
plasma was associated with glycocalyx disruption (increased
SDC-1 and ESM-1), endothelial inflammation [increased soluble
VCAM-1 (sVCAM-1)] and increased vascular permeability (Angpt-2).
During the late phase of metastasis, additional alterations in
haemostasis (increased PAI-1 and vWF), as well as a rise in ADM
and substantial fall in ADN concentration, were observed. In
conclusion, in a murine model of breast cancer metastasis, we
identified glycocalyx disruption, endothelial inflammation and
increased endothelial permeability as important events in early
metastasis, while the late phase of metastasis was additionally
characterised by alterations in haemostasis.
KEY WORDS: Endothelium, Murine 4T1 model of breast cancer,
Metastasis, Biomarkers, MicroLC/MS-MRM
INTRODUCTION
Despite the considerable progress in diagnostics and treatment of
cancer, mechanisms of metastasis are still not fully understood and
constitute an important barrier for the development of effective anti-
metastatic therapy (Zheng et al., 2013). Indeed, treatment failure
presently occurs in approximately 30% of breast cancer patients
(Mullan and Millikan, 2007). An important limitation in current
treatment strategies is the lack of reliable plasma biomarkers that
would allow for early detection of tumour metastasis and monitoring
of therapy efficacy. Recent attention has been paid to the analysis of
multi-biomarkers instead of a single-molecule approach as the
simultaneous imaging of multiple processes potentially involved in
metastasis may enable better identification of disease progression and
mechanisms underlying formation of metastases. Such a multi-
biomarker approach could be effectively used not only in early
diagnosis, but also in the selection of preventive and therapeutic
methods, potentially contributing to the development of precision
oncology (Mannello and Ligi, 2013; Schiffman et al., 2015; Gallo
Cantafio et al., 2018; Signoretti et al., 2018).
In recent years, attention has been focused on the significance of
the vascular endothelium in cancer metastasis. Healthy endothelial
cells inhibit tumour cell adhesion, transmigration and metastasis
formation (Blazejczyk et al., 2015), whereas endothelial
dysfunction, characterised by a shift towards decreased synthesis
of vasoprotective mediators and activation of pro-inflammatory and
pro-thrombotic molecules (Walczak et al., 2015; Frołow et al.,
2015), promotes cancer metastasis (Blazejczyk et al., 2015). In fact,
tumour cells respond to the chemokines and cell adhesion
molecules engaged in leukocyte trafficking (Roblek et al., 2015;
Schlesinger and Bendas, 2015). Abundant evidence suggests that
endothelial inflammation enhances the adhesion of cancer cells to
the endothelium and plays a major part in the development of
metastases (Franses et al., 2013; Rajendran et al., 2013). By
contrast, vasoprotective mediators, such as nitric oxide (NO) and
carbon monoxide (CO), inhibit cancer cell adhesion and
transmigration through the endothelium (Vahora et al., 2016;
Kourti et al., 2017; Stojak et al., 2018), while prostacyclin (PGI2)
and PGI2-releasing compounds have anti-metastatic effects
(Minami et al., 2015; Blazejczyk et al., 2016).
Given the key role of the endothelium inmetastasis formation, the
aim of this study was to characterise changes in endothelial function
that take place during the early and late phases of breast cancer
development in mice using a microflow liquid chromatography–
tandem mass spectrometry using multiple reaction monitoring
(microLC/MS-MRM)-based method that enables simultaneous
determination of specific sequences characteristic for 11 proteins
and one peptide biomarker defining endothelial function (Suraj
et al., 2018, 2019).Received 28 June 2018; Accepted 17 January 2019
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The panel of selected biomarkers included proteins involved in
various processes linked to endothelial dysfunction: glycocalyx
disruption – syndecan-1 (SDC-1), endocan (ESM-1); endothelial
inflammation – vascular cell adhesion molecule 1 (VCAM-1),
intercellular adhesion molecule 1 (ICAM-1), E-selectin (E-sel; also
known as Sele); vascular permeability – fms-like tyrosine kinase 1
(FLT-1), angiopoietin 2 (Angpt-2); and haemostasis – von
Willebrand factor (vWF), tissue plasminogen activator (t-PA; also
known as Plat), plasminogen activator inhibitor 1 (PAI-1; also
known as Serpine1), as well as other proteins/peptides related to
endothelial function – adrenomedullin (ADM), adiponectin (ADN;
also known as Acrp30 and Adipoq). The selected proteins represent
secreted proteins, receptors or cleaved surface proteins circulating
within plasma (Paulus et al., 2011; Walczak et al., 2015). In order to
study the progressive endothelial response to primary tumour
growth and breast cancer metastasis, we took advantage of the
murine model of spontaneously metastasising 4T1 mammary gland
carcinoma with prolonged development of metastasis (Pulaski and
Ostrand-Rosenberg, 2001; Buczek et al., 2018; Bailey-Downs et al.,
2014). This approach permitted quantification of biomarker
concentration in plasma in relation to primary tumour growth in
early and late phases of lung metastasis. Furthermore, we evaluated
the time course of changes of biomarkers not only in plasma, but
also in lungs and primary tumours, allowing determination of a
possible cellular origin of proteins/peptides circulating in plasma.
RESULTS
Basic characteristics of primary tumour and development
of metastasis in the lungs
Primary tumours (0.13±0.07 g) were detectable in the second week
after cancer cell inoculation, and the mean tumour weight
progressively increased throughout the course of the study to 2.39±
1.13 g in the fifth week, while tumour volume rose from 95 cm3 in
the second week to 1195 cm3 in the fifth week after 4T1 cell
inoculation. The onset of metastatic foci formation was
macroscopically observed in the lungs beginning from the second
week, but only a single metastatic nodule in one mouse per six was
noted, and increasing thereafter, finally resulting in 33 metastatic
foci in the fifth week (Table 1). Histopathological analysis of the
lungs revealed early (first week) and progressing development of
metastasis-related inflammation. The onset of the micrometastases
formation was noted in the second week after cancer cell inoculation
(Fig. 1). The robust metastasis development was noted in the fourth
and fifth week after tumour cell inoculation. Based on these results,
Table 1. Body and tissue weight, tumour growth, number of metastases, and values of haematological parameters
Parameter C for 1&2 1T 2T C for 4&5 4T 5T
BALB/c females
(Barbosa
et al., 2017)
Body weight minus
tumour weight (g)
16.74±0.54C,a 18.37±0.31 19.07±0.22B,a 19.53±0.54A,C 19.00±0.32 16.87±0.50A,B –
Weight of selected tissues
Lungs (g) 0.14±0.01 0.16±0.01B 0.17±0.00C 0.18±0.01A 0.22±0.02 0.39±0.02A,B,C –
Liver (g) 0.77±0.02 0.88±0.02 0.85±0.02a,b 0.83±0.03 1.00±0.04a 1.02±0.04b –
Spleen (g) 0.07±0.00a 0.08±0.00A,B 0.10±0.00Ca,b 0.08±0.00D,E 0.39±0.04A,D,b 0.48±0.03B,C,E –
Heart (g) 0.09±0.00 0.10±0,00 0.10±0.00 0.10±0.00 0.11±0.00 0.11±0.00 –
Kidney (g) 0.26±0.01 0.26±0.01 0.28±0.01 0.28±0.01 0.29±0.01 0.27±0.01 –
Brain (g) 0.43±0.01 0.47±0.01 0.46±0.01 0.46±0.01 0.47±0.01a 0.43±0.01a –
Tumour growth and metastasis
Primary tumour weight (g) – – 0.13±0.02A,B – 1.32±0.29A 2.39±0.26B –
Primary tumour
volume (cm3)
– – 95±10A,B – 756±154A 1195±71B –
No. metastatic foci in lungs – – 0.17#±0.09A – 14.20±2.73 32.67±3.41A –
Haematological parameters
%EOS (%) 1.69±0.25 1.76±0.13A,B 2.54±0.24C,a 2.19±0.32D,b 5.87±0.57A,C,D 4.58±0.35B,a,b 2.16±1.71
GRA (103/mm3) 0.90±0.07a 1.03±0.10A,B 4.97±0.64C,a 0.80±0.11D,E 106.58±25.36A,D 228.42±26.13B,C,E –
%GRA (%) 22.24±1.53A 28.04±1.58B,C 52.51±2.51A 21.89±1.28D,E 72.05±2.12B,D 69.76±1.56C,E –
LYM (103/mm3) 2.66±0.18 2.21±0.19A,B 3.23±0.24C,a 2.22±0.29D,E 24.97±6.28A,D,a 65.05±11.08B,C,E 2.57±8.31
%LYM (%) 74.37±1.57A 68.18±1.67B,C 42.37±2.61A,a 74.93±1.37D,E 20.03±2.14B,D 19.03±1.10C,E,a 71.76±5.90
MON (103/mm3) 0.08±0.01 0.07±0.01A,B 0.41±0.06C 0.04±0.01D,E 13.02±4.02A,D 38.53±6.36B,C,E 0.10±0.05
%MON (%) 3.39±0.24 3.79±0.20A,B 5.13±0.29C 3.19±0.36D,E 7.91±0.66A,D 11.21±0.50B,C,E 2.68±1.00
WBCs (103/mm3) 3.63±0.20 3.30±0.27A,B 8.60±0.89C 3.06±0.40D,E 145.33±35.00A,D 357.98±56.17B,C,E 3.56±1.07
HCT (%) 53.06±0.61 53.43±0.33 51.92±0.57 51.76±0.98 54.43±0.90 53.31±0.76 38.44±3.93
RBCs (106/mm3) 9.43±0.10 9.46±0.08 9.21±0.09 9.27±0.15 9.49±0.14 9.10±0.10 7.30±2.01
RDW (%) 11.34±0.09 11.52±0.12 11.64±0.10 11.53±0.09 11.82±0.15A 10.95±0.19A –
HGB (g/dl) 15.30±0.17 15.21±0.12 14.88±0.15a,b 15.10±0.33 15.73±0.24a 15.70±0.22b 11.85±1.56
MCH (pg) 16.24±0.07 16.08±0.07A 16.16±0.05B 16.28±0.17 16.58±0.12 17.27±0.19A,B –
MCHC (g/dl) 28.85±0.10 28.48±0.12a 28.67±0.10 29.18±0.38 28.91±0.17 29.48±0.21a 31.88±0.99
MCV (fl) 56.39±0.20 56.50±0.26 56.30±0.18a 55.70±0.25A,B 57.15±0.21A 58.53±0.59B,a 60.26±18.25
PLTs (103/mm3) 979.64±28.03 1015.61±26.12 912.58±26.62 1026.15±56.26 886.31±42.41 968.42±40.47 678.28±227.21
MPV (fl) 5.05±0.02 4.99±0.02A,B 5.05±0.03C,a 4.96±0.02D,E 5.25±0.04A,D,a 5.38±0.04B,C,E –
1T (n=14), 2T (n=20), 4T (n=13) and 5T (n=19); 1T, 2T, 4T and 5T represent 1, 2, 4 and 5 weeks after tumour cell inoculation. C, control group (C for 1&2; n=14; C
for 4&5; n=10).
White blood cells (WBCs), percentage of lymphocytes (%LYM), percentage of granulocytes (%GRA), percentage of eosinophils (%EOS), percentage of
monocytes (%MON), red blood cells (RBCs), platelets (PLTs), haemoglobin (HGB), haematocrit (HCT), mean cell volume (MCV), mean corpuscular
haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), red cell distribution width (RDW) and mean platelet volume (MPV).
Values marked with the same letter in a single row represent statistically significant differences; capital letter denotes P<0.01, small letter P<0.05.
#In the 2Tgroup,macroscopic analysis of the lungs revealed the presence of onemetastatic foci in oneof six investigated lungs. The presented value is amean±s.e.m.
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the first 2 weeks after tumour cell inoculation were defined as an early
metastatic period and the fourth and fifth weeks as the late metastatic
phase – compatible with our previous work with this model (Buczek
et al., 2018; Chrabaszcz et al., 2018; Smeda et al., 2018).
Despite significantly increased weights of primary tumour, lungs,
liver and spleen, along with a slight decrease in brain weight, the late
metastatic stage was associated with reduced body weight,
suggesting cancer-related wasting of the organism. Heart, kidneys
and bones from the tumour-bearing mice did not exhibit any
abnormal morphological features or any visible tumour foci, and
resembled the organs of control animals (Table 1).
Changes in blood count
The changes in white blood cell (WBC) counts were already visible
during the first week after 4T1 tumour cell inoculation but
statistically significant differences in blood cell counts were noted
in the second week and progressed thereafter. The changes included
an increase in total counts of WBCs, granulocytes (GRA),
lymphocytes (LYM) and monocytes (MON), and an increase in
the percentage of granulocytes (%GRA), monocytes (%MON) and
eosinophils (%EOS), with a concomitant reduction in the
percentage of lymphocytes (%LYM), although the absolute
number of LYM increased (Table 1).
Changes in plasma concentration of endothelial biomarkers
in the early phase of metastasis
In the first week after cancer cell inoculation, marked glycocalyx
disruption (SDC-1 and ESM-1) and notable activation of pro-
inflammatory adhesion molecules [soluble VCAM-1 (sVCAM-1)]
were detected. Plasma concentration of SDC-1 rose from 23.41±1.88
to 42.71±4.43 pmol/ml and ESM-1 from 0.36±0.02 to 0.53±
0.06 pmol/ml (Fig. 2A), whereas sVCAM-1 increased from 3.60±
0.57 to 7.17±0.58 pmol/ml (Fig. 3A). In the lungs, during the first
week after cancer cell inoculation, only ADN concentration
decreased, from 9.98±0.69 to 5.42±0.47 pmol/ml (Fig. 4B).
In the second week after cancer cell inoculation, plasma
concentrations of SDC-1, ESM-1 and sVCAM-1 (Figs 2A and
3A) diminished to values observed in control animals, while plasma
concentration of Angpt-2 rose from 146.17±8.31 to 228.93
±8.57 pmol/ml (Fig. 4A). Plasma concentration of other
Fig. 1. Histopathological analysis of the Haematoxylin- and Eosin-stained lungs. (A) Histology of the lungs in subsequent weeks after 4T1 tumour cell
inoculation. (B) Higher-magnificationmicrophotographs confirming the presence of inflammation, hyperaemia, reduction in alveolar volume andmicrometastases
2 weeks after tumour cell inoculation in comparison to control group. C, control group (respective control groups are presented: C for 1&2 and C for 4&5); 1T, 2T,
4T, 5T, groups of tumour-bearing mice in subsequent (1, 2, 4 and 5) weeks after tumour cell inoculation. Scale bars: 100 µm (A), 20 µm (B).
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determined biomarkers did not differ significantly. In the lungs and
primary tumours, all biomarkers were measurable, but the
differences were not significant.
Changes in plasma concentration of endothelial biomarkers
during the late phase of metastasis
In the fourth and fifth week after cancer cell inoculation, glycocalyx
disruption (SDC-1), endothelial inflammation (sVCAM-1, sE-sel)
and increased vascular permeability (Angpt-2) were also noted.
However, in contrast to the early phase, a significant rise in ADM
plasma concentration and substantial fall in ADN and sICAM-1
concentrations, as well as alterations in the levels of haemostatic
biomarkers (vWF, PAI-1), were observed (panel A in Figs 2-5).
In the lungs, during the fifth week after tumour cell inoculation,
the concentration of certain proteins increased, e.g. SDC-1
increased from 1.51±0.21 to 5.00±0.60 pmol/ml, VCAM-1 rose
from 2.00±0.32 to 4.68±0.50 pmol/ml, E-sel was elevated from
191.53±19.06 to 597.49±54.05 pmol/ml, Angpt-2 increased
from 72.12±6.88 to 219.88±33.25 pmol/ml, FLT-1 increased from
27.88±2.62 to 95.20±13.62 pmol/ml and PAI-1 rose from 43.00±
3.60 to 142.70±13.62 pmol/ml (panel B in Figs 2-5).
In turn, the primary tumours in the late phase of metastasis
exhibited high concentrations of ESM-1 (fourth week: 31.10±
6.59 pmol/ml, fifth week: 14.93±2.94 pmol/ml), VCAM-1 (fourth
week: 5.92±0.63 pmol/ml, fifth week: 4.73±0.24 pmol/ml), FLT-1
(fourth week: 104.52±13.97 pmol/ml, fifth week: 56.38±
3.50 pmol/ml), ADM (fourth week: 13.44±1.04 pmol/ml, fifth
week: 12.73±1.21 pmol/ml) as well as vWF (fourth week: 898.23±
94.63 pmol/ml, fifth week: 1325.87±132.45 pmol/ml) (panel B in
Figs 2-5).
DISCUSSION
In the present work, a murine model of spontaneously metastasizing
4T1 mammary gland carcinoma with a low number of inoculated
tumour cells (1×104) was used, which resulted in a prolonged
development of metastases (Buczek et al., 2018; Bailey-Downs
et al., 2014). This is in contrast to a number of other studies in which
the authors employed 1×106 4T1 tumour cells (for example, Tao
et al., 2008), which led to robust metastases in the lungs, heart, liver,
kidney, spleen and bones along with a shorter time period needed to
achieve the end-stage of disease. Our approach enabled us to easily
discern the early (first-second week) and late (fourth-fifth week)
phases ofmetastasis defined on the basis ofmetastatic foci formation
detected macroscopically in the lungs and by lung histology as also
characterised in our previous works (Buczek et al., 2018; Smeda
et al., 2018; Chrabaszcz et al., 2018). The early phase of metastasis
in this model (first-second week after cancer cell inoculation) was
characterised by the presence of the primary tumour (which started
to be palpable after the first week following cancer cell inoculation),
pulmonary inflammation and micrometastases (Buczek et al., 2018;
Smeda et al., 2018). The latter was also confirmed by Fourier-
transform infrared (FTIR) spectroscopic imaging, which seemed to
be a sensitive approach for the identification and visualisation of
early pulmonary micrometastases and macrometastases 2 and 3
weeks after cancer cell inoculation, respectively, in the same murine
model of metastatic 4T1 breast cancer (Chrabaszcz et al., 2018;
Augustyniak et al., 2018). The late phase of metastasis (fourth-fifth
week) was reflected by large primary tumours and numerous
metastases easily detected macroscopically as well as robust blood
count changes, including pronounced leukocytosis.
The robust increase in WBC count of 4T1 tumour-bearing mice
was also reported previously (Wang et al., 2015), and was linked to
medullary and extramedullary haematopoiesis (Younos et al., 2011,
2012), with expansion of myeloid-derived suppressor cells (MDSCs)
promoting metastases development (Younos et al., 2011; Cao et al.,
2014; Kus et al., 2018). The increased leukocytosis underlines robust
cancer-associated systemic inflammation as evidenced also by
increased plasma concentration of pro-inflammatory cytokines, e.g.
interleukin 6 (IL-6), as reported earlier in the same model of 4T1
tumour-bearing mice (Buczek et al., 2018).
Fig. 2. Concentration of biomarkers of
glycocalyx disruption. Biomarker
concentration in plasma (A), and lungs and
primary tumours (B) are shown. Areas boxed
with a dashed line show proteins that exhibited
concentration changes in the early metastatic
phase; areas boxed with a solid line show
proteins that exhibited concentration changes
in the late metastatic phase. C, control group
(respective control groups are presented: C for
1&2 and C for 4&5); 1T, 2T, 4T, 5T, groups of
tumour-bearingmice in subsequent (1, 2, 4 and
5) weeks after tumour cell inoculation; above
the columns statistically significant changes
are marked to respective control groups, in
primary tumours between the analysed groups;
on the right side of the figure are presented
statistically significant changes only between
the tumour-bearing groups of mice; data are
represented as means±s.e.m.; *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001.
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The major finding of the present work was the demonstration that,
in the first week after cancer cell inoculation, glycocalyx disruption
(SDC-1 and ESM-1), endothelial inflammation (sVCAM-1) and
increased vascular permeability (Angpt-2) were present, as evidenced
by elevated plasma concentrations of respective biomarkers. These
results are in line with the early involvement of alterations in the
function of pulmonary endothelium in cancer cell extravasation to
the lungs (Franses et al., 2013). In fact, the adhesion of cancer cells to
the endothelium and subsequent metastasis were shown to be
facilitated by endothelial glycocalyx removal (Gasic and Gasic,
1962; Rai et al., 2015). Thus, shedding of endothelial glycocalyx
seems to be a prerequisite for the early pulmonary metastasis of 4T1
breast cancer cells. The early phase of metastases formation was also
associated with increased plasma concentration of Angpt-2, thereby
suggesting changes in endothelial permeability (Felcht et al., 2005).
Furthermore, glycocalyx disruption (Cahill and Redmond, 2016;
Kurzelewski et al., 2005) was associated with an endothelial
NO-deficiency state, relevant to the early pulmonary response to
breast cancer metastasis (Tousoulis et al., 2012). Indeed, Smeda et al.
(2018) in the same model demonstrated decreased endothelial nitric
oxide synthase (eNOS) activity, resulting in a lowNO-production state
in the pulmonary endothelium during the very early phase of breast
cancer pulmonary metastasis, even preceding the onset of its
phenotypic switch toward a mesenchymal phenotype (EndMT)
(Smeda et al., 2018). Altogether, our results showing increased
plasma concentrations of SDC-1, ESM-1, sVCAM-1 and Angpt-2
seem to reflect a local pulmonary endothelial response to murine
metastatic breast cancer development involving glycocalyx disruption,
endothelial inflammation and increased endothelial permeability that,
together with a low-NO pulmonary microenvironment – reported
previously in this model (Smeda et al., 2018; Buczek et al., 2018) –
might all promote metastases development. These results are fully
compatible with the important pathophysiological role of the alterations
in endothelial function in metastasis (Mierke, 2008; Gasparics et al.,
2016; Wieland et al., 2017).
Given that the pulmonary endothelial surface represents
approximately 30% of the total endothelial surface of the
cardiovascular system, we claim that an early increase in
biomarkers of endothelial dysfunction reflects a pulmonary
endothelium response to early metastasis. On the other hand, it
seems unlikely that systemic endothelium contributes to these early
changes in plasma biomarkers of endothelial dysfunction. We
previously demonstrated that the systemic endothelium was not
affected in this model until the late stage of metastasis and the
occurrence of pronounced systemic inflammation (Buczek et al.,
2018).
Fig. 3. Concentration of biomarkers of
inflammation. Biomarker concentration in
plasma (A), and lungs and primary tumours
(B) are shown. Areas boxed with a dashed line
show proteins that exhibited concentration
changes in the early metastatic phase; areas
boxed with a solid line show proteins that
exhibited concentration changes in the late
metastatic phase. C, control group (respective
control groups are presented: C for 1&2 and C
for 4&5); 1T, 2T, 4T, 5T, groups of tumour-
bearing mice in subsequent (1, 2, 4 and 5)
weeks after tumour cell inoculation; above the
columns statistically significant changes are
marked to respective control groups, in primary
tumours between the analysed groups; on the
right side of the figure are presented
statistically significant changes only between
the tumour-bearing groups of mice; data are
represented as means±s.e.m.; *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001.
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The late phase of cancer metastasis was also associated with
glycocalyx disruption, endothelial inflammation and increased
vascular permeability. There were, however, certain differences in
the pattern of detected endothelial biomarkers in the late versus
early phase of metastasis.
During the late phase of metastasis, concentrations of not only
sVCAM-1 but also sE-sel were significantly increased within
plasma. Interestingly, the concentration of E-sel in the lungs was
also considerably raised, suggesting that pulmonary endothelium
could constitute the major cellular origin of sE-sel during the late
phase of pulmonary metastasis (Fig. 3), in agreement with a number
of reports showing the role of sE-sel in cancer cell progression, for
example in homing of metastatic cancer cells (Gogali et al., 2010).
In contrast to sVCAM-1, the plasma concentration of sICAM-1 fell
considerably during the late phase of metastasis. This finding is
surprising, as is the parallel fall in SDC-1, sVCAM-1, Angpt-2 and
vWF in plasma in the fifth week after cancer cell inoculation, and
therefore requires further study (Zhang et al., 2018).
The important difference in the pattern of plasma biomarkers in
early and late phases of metastasis was the late alterations in
haemostasis, as evidenced by increased plasma concentration of
vWF and PAI-1 without any significant changes in t-PA (Fig. 5A).
Fig. 4. Concentration of biomarkers of
endothelial permeability and biomarkers
pathophysiologically linked with breast
cancer metastasis (ADM, ADN). Biomarker
concentration in plasma (A), and lungs and
primary tumours (B) are shown. Areas boxed
with a dashed line show proteins that exhibited
concentration changes in the early metastatic
phase; areas boxed with a solid line show
proteins that exhibited concentration changes
in the late metastatic phase. C, control group
(respective control groups are presented: C for
1&2 and C for 4&5); 1T, 2T, 4T, 5T, groups of
tumour-bearing mice in subsequent (1, 2, 4
and 5) weeks after tumour cell inoculation;
above the columns statistically significant
changes are marked to respective control
groups, in primary tumours between the
analysed groups; on the right side of the figure
are presented statistically significant changes
only between the tumour-bearing groups of
mice; data are represented as means±s.e.m.;
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Interestingly, PAI-1 concentration increased not only in plasma, but
also in the lungs, while vWF rose in primary tumours, suggesting a
possible different cellular source of these two major regulators of
haemostasis: lungs and tumour cells, respectively. Indeed, PAI-1 is
known to be produced by pulmonary endothelium (Muth et al.,
2004) and its plasma concentration correlated with tumour
progression (Lampelj et al., 2015).
In turn, high expression of vWF in primary tumours is compatible
with the notion that vWF is required in the initial phase of metastatic
foci formation, independent of its role in haemostasis (Mochizuki
et al., 2012; Zucker andCao, 2012). Still, in our hands, a rise in plasma
vWF concentration was noted rather late, suggesting that vWFmay be
implicated during the late phase of murine breast cancer metastasis.
The interesting finding was that the late phase of breast cancer
metastasis was associatedwith a rise inADM and fall inADN plasma
concentration (Fig. 4A). Hinson et al. (2000) and Oehler et al. (2003)
reported that ADM plays an important role in tumour angiogenesis in
breast cancer by increasing the intra-tumour blood flow as well as the
development of lymph node metastases. In fact, in our hands, we
detected an increased concentration of ADM not only in plasma, but
also in the primary tumour, suggesting that the growing primary
breast tumour might have contributed to the increased plasma
concentration of this molecule (Keleg et al., 2007).
A substantial fall of ADN concentration in plasma was associated
with a significant fall in ADN content in lungs but not in the primary
tumour. Thus, it might be assumed that cancer-wasted adipose
tissue, the major cellular origin of a decreased ADN concentration in
plasma, was associated with a reduction of ADN within the lungs.
The role of ADN in cancer progression is still controversial. It has
been shown that ADN inhibits adhesion, invasion and migration of
breast cancer cells (Saxena and Sharma, 2010). In the study of Man
et al. (2010), adiponectin treatment significantly inhibited liver
tumour growth and metastasis by suppression of tumour
angiogenesis. By contrast, Landskroner-Eiger et al. (2009) and
Denzel et al. (2009) showed that breast cancer tumour
vascularisation is stimulated by ADN.
Even though, during the late phase of metastasis, the concentration
of FLT-1 increased in the lungs, the plasma concentration of sFLT-1
remained unchanged. Apparently, in the setting of breast cancer
metastasis, systemic Angpt-2-dependent mechanisms may be more
important than systemic vascular endothelial growth factor (VEGF)-
dependent mechanisms, even though the latter is of importance in
patients with breast cancer (Thielemann et al., 2010). In patients with
gastric cancer, elevated Angpt-2 was strongly associated with liver
metastasis (Hacker et al., 2016), suggesting that increased plasma
concentration of Angpt-2 may indeed represent an important
Fig. 5. Concentration of biomarkers of
haemostasis. Biomarker concentration in
plasma (A), and lungs and primary tumours
(B) are shown. Areas boxed with a dashed line
show proteins that exhibited concentration
changes in the early metastatic phase; areas
boxed with a solid line show proteins that
exhibited concentration changes in the late
metastatic phase. C, control group (respective
control groups are presented: C for 1&2 and C
for 4&5); 1T, 2T, 4T, 5T, groups of tumour-
bearing mice in subsequent (1, 2, 4 and 5)
weeks after tumour cell inoculation; above the
columns statistically significant changes are
marked to respective control groups, in primary
tumours between the analysed groups; on the
right side of the figure are presented
statistically significant changes only between
the tumour-bearing groups of mice; data are
represented as means±s.e.m.; *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001.
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biomarker of increased endothelial permeability associated with the
progression of various types of cancer.
Determination of biomarkers in lung homogenates and primary
tumours indicated a possible source of their elevated concentration
in plasma. Accordingly, pulmonary endothelium of metastatic lungs
seems to contribute to the number of plasma biomarkers raised
during the late phase of metastasis (PAI-1, Angpt-2, sFLT-1, sE-
sel), whereas primary tumours were an important source of vWF,
the concentration of which progressively increased in primary
tumours and in plasma along with the progression of breast cancer.
Altogether, even though all selected proteins analysed here were
previously reported to be relevant to cancer development [ESM-1
(Yang et al., 2015), PAI-1 (Andreasen, 2007; Duffy et al., 2014),
t-PA (Corte et al., 2005), sFLT-1 (Thielemann et al., 2010), vWF
(Luo et al., 2012; Zucker and Cao, 2012), sE-sel (Mann and Tanaka,
2012), sVCAM-1 (Silva et al., 2006), sICAM-1 (O’Hanlon et al.,
2002; Schröder et al., 2011), SDC-1 (Szatmári et al., 2015), Angpt-2
(Li et al., 2015)], in the present work, we specifically characterised
the profile of their changes during the early and late phases of
metastasis. Of course, in the current work, we did not provide the
experimental results to show the pathophysiological role of a given
pathway represented by a measured biomarker, and this is a
limitation of this study.
Nevertheless, to the best of our knowledge, our endothelium-
oriented approach that aimed to profile endothelial response to breast
cancer development and metastasis is unprecedented. Our results
provide novel insights into the endothelial response to breast cancer
development and metastasis in the well-validated murine model of
breast cancer metastasis. We identified glycocalyx disruption,
endothelial inflammation and increased endothelial permeability as
important events in early pulmonary metastasis in this model, while
the late phase of metastasis was additionally featured by alterations in
haemostasis and changes in the adrenomedullin and adiponectin
pathways.We believe that our methodologymay offer a novel tool to
profile endothelial phenotype in humans, not only in cancer but also
in various diseases associated with endothelial dysfunction, as has
been recently shown in our pilot study in humans (Suraj et al., 2019).
MATERIALS AND METHODS
Cell culture
Cells from the murine mammary gland tumour cell line 4T1 were purchased
from the American Type Culture Collection (ATCC) in 2015 and then
kindly donated by Joanna Wietrzyk’s group (Ludwik Hirszfeld Institute of
Immunology and Experimental Therapy, Polish Academy of Sciences,
Wroclaw, Poland) in the frame of the collaborative STRATEGMED1/
233226/11/NCBR/2015 project. The methodology of preparation of cells
for the studies in the 4T1 murine model of breast cancer was established by
JoannaWietrzyk’s group. Cells were always used at the second passage after
seeding cells from frozen aliquots and were regularly tested for mycoplasma
contamination using the MycoAlert Mycoplasma Detection Kit (Lonza
Group Ltd, Basel, Switzerland). Cells were maintained in T75 culture flasks
as an adherent monolayer in RPMI 1640 GlutaMAX medium (Gibco, Life
Technologies, Carlsbad, USA) supplemented with 10% foetal bovine serum
(Gibco, Life Technologies), 1 mM sodium pyruvate (Sigma-Aldrich, St
Louis, USA) and antibiotic antimycotic solution (100 units/ml penicillin,
100 μg/ml streptomycin and 25 μg/ml amphotericin B; Sigma-Aldrich).
Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2.
Animal model
A total of 90 7- to 8-week-old BALB/c female mice were obtained from the
Center for Experimental Medicine (Medical University of Bialystok,
Poland). Mice were fed a standard laboratory diet, Altromin 1324 Total
Pathogen Free for mice with 3188 kcal/kg, including 24% of calories from
proteins, 12% of calories from fat and 74% calories from carbohydrates
(Altromin, Poznan, Poland), and had free access to water. Tumour cells
of murine mammary carcinoma 4T1 (1×104 cells/mouse) suspended
in 0.05 ml of Hanks’ Balanced Salt Solution (HBSS) (Gibco, Life
Technologies) were orthotopically inoculated into the right mammary fat
pad. Analyses were conducted in different numbers of animals (n) per each
group after 1 (n=14), 2 (n=20), 4 (n=13) and 5 (n=19) weeks following
tumour cell inoculation. The following abbreviations were used for the
consecutiveweeks after inoculation: 1T, 2T, 4T and 5T, respectively. Healthy
BALB/c mice were utilised as two control groups: the control group for the
first and second week (C for 1&2; n=14) and for the fourth and fifth week
(C for 4&5; n=10). The numberof animals and procedures in each groupwere
specified according to the approval of the Local Ethical Committee for
Experiments on Animals at the Jagiellonian University (Krakow, Poland).
Experiments were conducted in accordance with the ethical standards, and
according to the Declaration of Helsinki and national and international
guidelines, with approval by the authors’ institutional review board.
Blood and tissue collection, and haematological analysis
Blood was collected from the right ventricle under anaesthesia using a
mixture of ketamine (100 mg/ml) (Vetoquinol, Gorzow Wielkopolski,
Poland) and xylazine (10 mg/ml) (Sigma-Aldrich), and a 0.025 ml mixture
for 10 g body weight was injected intraperitoneally. Blood samples were
collected into syringes containing dipotassium ethylenediaminetetraacetic
acid (K2EDTA) (1.6 mg/ml) (Aqua-Med, Lodz, Poland). WBCs, %LYM,
%GRA, %EOS, %MON, red blood cells (RBCs), platelets (PLTs),
haemoglobin (HGB), haematocrit (HCT), mean cell volume (MCV), mean
corpuscular haemoglobin (MCH), mean corpuscular haemoglobin
concentration (MCHC), red cell distribution width (RDW) and mean
platelet volume (MPV) were determined with the aid of an ABC Vet
analyser (Horiba, Kyoto, Japan). The blood not destined for haematological
analysis was immediately mixed with MS-SAFE protease and phosphatase
inhibitor cocktail (PIC) (Sigma-Aldrich) in a ratio of 100:1 and centrifuged at
664 g for 10 min at 4°C. The resulting plasmawas then transferred into Protein
LoBind tubes, split into 30 µl aliquots and stored at −80°C until further use.
Assessment of primary tumours and number of metastases
in lungs
In order to remove the blood and ensure reliable analysis of the biomarkers
in the tissue, perfusion of the whole body with phosphate-buffered saline
(PBS, pH 7.4) was performed immediately subsequently to blood
collection. Primary tumours were dissected from the surrounding tissues,
measured with a calliper and weighed. Tumour volume (V; in mm3) was
calculated with the following formula (Jiang et al., 2010) (with length and
width of the tumour measured in mm):
V ¼ 0:52 length of tumour  ðwidth of tumourÞ2: ð1Þ
Isolated lungs for biomarker analysis were washed after dissection in
sodium chloride 0.9% solution (0.9% NaCl) (VWR, Radnor, USA) and
weighed. For histological analysis, lungs were not perfused and were fixed
with 4% formalin buffered solution (Chempur, Piekary Slaskie, Poland).
The number of metastatic sites in lungs was macroscopically counted. For
overall analysis of animal health condition, body weights were checked on
the day of tumour cell inoculation and in the weeks thereafter of the
experiment. Additionally, the weights of selected organs, namely the lungs,
liver, kidney, spleen, brain and heart, were also noted.
Histopathological analysis
Phosphate-buffered formalin (pH 7.4, 4%) was used for fixing lungs.
Haematoxylin and Eosin were used for staining of paraffin-embedded
sections (three sections per microscope slide). Ten random images were
taken at 200×, and additionally at 400×, with an Olympus light microscope
BX51 (Olympus Corporation, Tokyo, Japan).
Preparation of lung and primary tumour homogenates
for biomarker determination
Tissue homogenates of lungs and primary tumours were prepared in PBS
with the addition of PIC in a ratio of 100:1 using a Precellys Evolution
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Tissue Homogenizer (Montigny-le-Bretonneux, France) (chilled with
liquid nitrogen, 7500 rpm, 3 cycles, 30 s break). The homogenates were
centrifuged (4°C, 10,000 g, 15 min) and the supernatant was frozen at
−80°C until analysis.
MicroLC/MS-MRM analysis of biomarkers
The key part of the study was to establish the concentration of 12 selected
biomarkers in mouse plasma, lung and primary tumour homogenates using
the microLC/MS-MRM method. For each biological sample from three
matrices, the multiplexed analysis of the selected 11 proteins and one peptide
was performed in one, single analytical run. The panel included endothelial
proteins, specifically SDC-1, ESM-1, VCAM-1, E-sel, ICAM-1, Angpt-2,
FLT-1, vWF, t-PA and PAI-1, as well as biomarkers pathophysiologically
linked with breast cancer metastasis, including ADN, the protein produced
by adipocytes that is known to display vasoprotective and pro-angiogenic
activity (Miłosz et al., 2007; Landskroner-Eiger et al., 2009), as well as
ADM, a peptide reported to contribute to breast cancer progression also
displaying pro-angiogenic activity (Oehler et al., 2003).
The detailed description of the sample preparation for microLC/MS-
MRM analysis considering the validation of the analytical method
developed for the analytes was included in Suraj et al. (2018, 2019). In
brief, total protein concentration in plasma, tissues and primary tumour was
assessed using a NanoDrop 8000 spectrophotometer (Thermo Fisher
Scientific, Waltham, USA). The samples were diluted to a concentration of
7 mg/ml using 25 mM ammonium bicarbonate (NH4HCO3) (Sigma-
Aldrich) and 210 µg of total protein was denatured with 10% solution of
sodium deoxycholate (Sigma-Aldrich) in 25 mM NH4HCO3, then diluted
with 25 mM NH4HCO3. Samples were reduced with 50 mM tris(2-
carboxyethyl)phosphine (TCEP) (Sigma-Aldrich) in 25 mM NH4HCO3
for 30 min at 60°C and alkylated in the dark with 100 mM iodoacetamide
(IAM) (Sigma-Aldrich) in 25 mM NH4HCO3 for 30 min at 37°C. Next, the
excess of IAM was quenched by the addition of 100 mM DL-dithiothreitol
(DTT) (Sigma-Aldrich) in 25 mM NH4HCO3. The incubation of the
samples lasted 30 min at 37°C. Digestion was carried out for 16 h at 37°C
with sequencing grade modified trypsin (SGM trypsin) in a 50:1 ratio
(substrate:enzyme) (Promega, Madison, USA). Prepared internal standard
peptide solutions obtained from dissolved powders of internal standard
peptides, synthesised and quality controlled by Innovagen (Lund, Sweden)
(Suraj et al., 2018, 2019), specific for each target peptide sequence
were implemented just before ceasing the digestion. Finally, this
process was stopped by the addition of formic acid (FA) (Sigma-
Aldrich) at a final concentration of 0.5% v/v. Next, sodium deoxycholate
was pelleted. The sample supernatant obtained after centrifugation (3000 g
for 10 min at 23°C) was desalted and concentrated by the micro-solid
phase extraction (µSPE) procedure using the Oasis HLB elution plate with
2 mg of sorbent mass per well (Waters, Milford, USA). Briefly, the resin
was rinsed with methanol and equilibrated with water (H2O). The sample
was loaded, washed with water and eluted with a 50% solution of
acetonitrile (ACN) (Sigma-Aldrich) in deionized water with an addition
of 0.1% FA. Samples were lyophilized and resuspended in 50 µl 20% ACN
in H2O.
The analysis of all samples was performed using the microLC/MS-MRM
method. In the analysed samples, the digested peptide fragments specific for
the selected proteins were first resolved using the microLC system (Nexera
Shimadzu, Kyoto, Japan). Each sample was loaded (2 µl) to the analytical
column: ACE, C8 analytical column (150×1.0 mm i.d., 5 µm, 300 Å,
Advanced Chromatography Technologies Ltd, Aberdeen, UK). The mobile
phases consisted of 0.1% FA in ACN v/v and 0.1% FA in H2O (v/v). The
total time of analysis was 50 min in a gradient elution. The flow rate was
100 µl/min.
For mass detection, a highly sensitive mass spectrometer QTrap 5500
(Sciex, Framingham, USA) was applied. The mass spectrometer was
operated with the following parameters: ion spray voltage: 5500 V; source
temperature: 400°C; curtain gas: 25 psi; ion source gas 1: 35 psi; ion source
gas 2: 50 psi. The values for collision energy (CE), declustering potential
(DP), entrance potential (EP) and collision cell exit potential (CXP) were
specific for each transition. Two transitions free of signal interferences
when present in a plasma-digest background were selected as the final ion
pairs for use in the final assay. A list of transitions and optimisation
parameters were presented in detail in methodological publications by Suraj
et al. (2018, 2019).
The obtained data were processed by Analyst software version 1.6.2
developed by the SCIEX company (Framingham, USA). All integrated
peaks were checked to ensure correct peak detection.
Statistical analysis
Data were presented as means±s.e.m. Assessments of normality (Shapiro–
Wilk test) and equality of variances (Levene test) were performed. To assess
the statistical significance of the results, a one-way analysis of variance
(ANOVA) with Tukey’s post hoc test or a non-parametric Kruskal–Wallis
test were performed (two-tailed). The results were evaluated with Statistica
12.0 software (StatSoft, Tulsa, USA), with P-values of less than 0.05
regarded as statistically significant.
Results were presented in comparison to the two control groups. Despite
alterations between these control groups, there were no statistically
significant changes between them except for the animal weights, which
differed significantly.
A summary workflow diagram of the study design is portrayed in Fig. 6.
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(2005). Tissue-type plasminogen activator (tPA) in breast cancer: relationship with
clinicopathological parameters and prognostic significance. Breast Cancer Res.
Treat. 90, 33.
Denzel, M. S., Hebbard, L. W., Shostak, G., Shapiro, L., Cardiff, R. D. and
Ranscht, B. (2009). Adiponectin deficiency limits tumor vascularization in the
MMTV-PyV-mT mouse model of mammary cancer. Clin. Cancer Res. 15,
3256-3264.
Duffy, M. J., McGowan, P. M., Harbeck, N., Thomssen, C. and Schmitt, M.
(2014). uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in
level-of-evidence-1 studies. Breast Cancer Res. 16, 428.
Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A.,
Kienast, Y., Vettel, C., Loos, E. K. et al. (2005). Angiopoietin-2 differentially
regulates angiogenesis through TIE2 and integrin signaling. J. Clin. Invest. 122,
1991-2005.
Franses, J. W., Drosu, N. C., Gibson, W. J., Chitalia, V. C. and Edelman, E. R.
(2013). Dysfunctional endothelial cells directly stimulate cancer inflammation and
metastasis. Int. J. Cancer 133, 1334-1344.
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